Mobile

Pembrolizumab (MK-3475) in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-004026-17

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Objective 1: To evaluate anti-tumor activity of pembrolizumab (MK-3475), with regards to absence of high risk NMIBC or progressive disease, as determined by cystoscopy, cytology, biopsy (if applicable) and radiologic imaging by central pathology and radiology review. Objective 2: To evaluate anti-tumor activity of pembrolizumab (MK-3475) in PD-L1 positive subjects with regards to absence of high risk NMIBC or progressive disease, as determined by cystoscopy, cytology, biopsy (if applicable) and radiologic imaging by central pathology and radiology review.

Critère d'inclusion

  • Non-Muscle Invasive Bladder Cancer (NMIBC)

Liens